skip to content
https://research-5iresearch.lpages.co/free-trial-5i-research-5i-blog/
Detailed Quote
5i Report
Rating
B+

Review of Savaria

JUL 15, 2019 - Accessibility and medical product provider facing some cost issues after completing significant acquisitions. Rating maintained at 'B+'.

Download Report
Company Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions

Q: Hi Peter, Ryan, and Team,

We have a 2.5% position in CN, and are a bit underweight in the industrial sector. Would the ongoing rail line blockade and slight decline in share price represents a buying opportunity? Or would a new investment into WSP, for example, be a better strategy? (Our other industrials are CAE, SIS, and TFII). Thanks in advance for your valued advice.

Read Answer Asked by Jerry on February 14, 2020

Q: Aside from the obvious demographic appeal of increasing demand for Savaria's products for aging persons with disabilities, it strikes me that as seniors have increasing need for cash flow in later years, they will turn more and more to reverse mortgages. This will lock them in as long as they can live in the financed home. That said, faced with disabilities that might otherwise force them to leave their home, purchasing Savaria's products will be the only solution. Do you agree? Do analysts understand this market force?

Read Answer Asked by Geoffrey on February 10, 2020
Insiders
CMS Buy Now
Share Information
News and Media